Strong Q2 Results and Raised Revenue Guidance Drive Natera’s (NTRA)Outperformance
Carillon Tower Advisers' Q3 2026 investor letter highlights Natera (NTRA) as a top performer, contributing 0.93% to returns. The diagnostics company reported strong Q2 results and raised full-year revenue guidance, driven by its Signatera oncology test. NTRA's stock surged 36.18% year-to-date, closing at $311.98 on November 10, 2026, with a market cap of $45.23 billion.
How this was made

The 30-second read
Why it matters
It links Natera’s outperformance to strong Q2 results, a meaningful full-year revenue outlook increase, Signatera volume growth, and an FDA companion diagnostic approval for bladder cancer, plus planned Japan launch and additional reimbursement approvals.
Market read
Traders may update positioning in NTRA based on the stated guidance raise and the reinforcement from FDA approval and expanding clinical adoption signals.
What to watch
The excerpt does not quantify the magnitude of the revenue outlook increase or provide reimbursement uptake metrics, leaving uncertainty around how quickly volumes translate into sustained revenue growth.
Background
The piece is an excerpt from Carillon Eagle Mid Cap Growth Fund’s Q3 2026 investor letter discussing mid-cap performance and highlighting Natera’s contribution.
Ticker impact
Carillon’s letter says Natera’s strong Q2 results led management to meaningfully raise full-year revenue outlook, boosting Signatera testing volumes and citing FDA companion diagnostic approval.
Likely upward bias as the market prices in higher full-year revenue and continued adoption of Signatera supported by FDA-labeled use.
The article attributes a guidance increase to strong Q2 performance and adds specific product and regulatory catalysts (FDA approval, volume growth), but it is framed as an investor-letter excerpt rather than a primary earnings release.
Market effects
Supports sentiment for liquid-biopsy and molecular diagnostics names, especially those tied to oncology companion diagnostics and reimbursement expansion narratives.
Limited direct regional impact; Japan launch and reimbursement approvals are incremental catalysts for adoption outside the US.
Moderate, as Japan launch plans and multi-indication reimbursement progress can broaden the addressable market for cell-free DNA testing.
Counterpoint
Investor-letter framing may lag the market’s initial reaction to Q2 results and guidance, so incremental impact could be smaller if the guidance raise is already widely known.
Key entities
- public_companyNatera, Inc.
Diagnostics company focused on cell-free DNA testing, with oncology test Signatera and related regulatory and reimbursement catalysts.



